A Phase I Study of iPS Cell Generation From Patients With COPD

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01860898

Enrollment

Registered

2013-05-23

Start date

2009-09-30

Completion date

2014-10-28

Last updated

2022-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer of Lung, Cancer of the Lung, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, COPD, Lung Cancer, Lung Diseases, Obstructive, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Emphysema, Pulmonary Neoplasms, Respiratory Tract Diseases, Thoracic Diseases

Keywords

lung, cancer, thoracic, chest, pulmonary

Brief summary

As part of the long-term goal of successfully implementing tissue regeneration strategies in an individualized manner for patients with thoracic diseases including, but not limited to: cystic fibrosis, pulmonary fibrosis and pulmonary hypertension, the investigators will assess the feasibility of collecting skin biopsies from patients undergoing surgery for thoracic disease, culturing skin fibroblasts from the biopsy, and reprogramming these skin fibroblasts into induced pluripotent cells.

Interventions

OTHERSkin Biopsy

Biopsy samples will be taken as a 2mm x 2cm excision of a wedge of skin at the edge of the incision during your surgery at the Mayo Clinic Rochester. Such excisions are frequently done as part of routine skin closure for optimal skin cosmesis following the surgical procedure.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Undergoing Thoracic Surgery at the Mayo Clinic Rochester * Presence of a Thoracic Disease

Design outcomes

Primary

Measure	Time frame	Description
Feasibility	1 year	As part of the long-term goal of successfully implementing tissue regeneration strategies in an individualized manner for patients with thoracic diseases including, but not limited to: cystic fibrosis, pulmonary fibrosis and pulmonary hypertension, we will assess the feasibility of collecting skin biopsies from patients undergoing surgery for thoracic disease, culturing skin fibroblasts from the biopsy, and reprogramming these skin fibroblasts into induced pluripotent cells. Markers of induced pluripotent phenotype will be utilized to assess successful reprogramming.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026